AMARILLO, Texas, May 15 /PRNewswire/ -- Amarillo Biosciences, Inc.
(OTC Bulletin Board: AMAR.OB), has reached an agreement with Key Oncologics
(Pty) Ltd. (Key) for the development and marketing of ABI's low-dose orally
administered interferon alpha (IFN alpha) in South Africa, Zimbabwe, Botswana
and Namibia.
Dr. Joseph Cummins, Chairman and CEO of Amarillo Biosciences, said "We are
extremely pleased to establish a relationship with Key Oncologics for the
South African market. This is the first of several development and
commercialization agreements which we hope to conclude during the coming
months."
Key Oncologics, established in 1995 to meet the specialized needs of
cancer patients, is looking to expand its therapeutic base. Key is the
licensee of Proleukin(R) (IL-2) and Cardioxane(R) (dexrazoxane) from Chiron
Corporation and AmBisome(R) and DaunoXome(R) from Nexstar Pharmaceuticals,
Inc. for South Africa.
"We are particularly pleased to have the opportunity to work with Amarillo
Biosciences in the market development of oral IFN alpha which we consider to
be a novel product", said Magriet de Wet, Managing Director of Key. Key will
initially participate in ABI's clinical trial program for hepatitis C.
As part of the agreement, Amarillo will supply IFN alpha to Key. Key will
have the responsibility for obtaining all government approvals in South Africa
for both clinical trials and marketing.
Amarillo Biosciences, founded in 1984, is a pioneer in the development of
low-dose orally administered interferon alpha as a treatment for a variety of
conditions, including Sjogren's syndrome, fibromyalgia syndrome, hepatitis B
and C and opportunistic infections in patients who are HIV positive. ABI is
conducting a Phase III clinical program in Sjogren's syndrome in the United
States.
Except for the historical information contained herein, the matters
discussed in this news release are forward-looking statements that involve
risks and uncertainties, including uncertainties related to product
development, uncertainties related to the need for regulatory and other
government approvals, dependence on proprietary technology, uncertainty of
market acceptance of oral interferon alpha or the company's other product
candidates and other risks detailed from time to time in the company's filings
with the Securities and Exchange Commission. In particular, see "Item 1.
Description of Business" of the company's Form 10-KSB for the year ended
Dec. 31, 1999.
SOURCE Amarillo Biosciences, Inc.
 back to top
Related links:
http://www.amarbio.com
CONTACT:
John M. Smith, Vice President Marketing &
Business Development International of Amarillo Biosciences, Inc.,
806-376-1741, #24, or jmsmith@amarbio.com
|
